
ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting ...
New data at CROI 2025 show zero cases of HIV acquisition reported with Apretude (cabotegravir long-acting (CAB LA) for PrEP) in varied clinical settings and populations in two implementation studies in the U.S. and Brazil Data for Cabenuva (cabotegravir + …